Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
University of Chicago
University of Chicago
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC
Trishula Therapeutics, Inc.
Intensity Therapeutics, Inc.
Rutgers, The State University of New Jersey
National Institutes of Health Clinical Center (CC)
Incyte Corporation